2023年欧洲内科肿瘤学（ESMO）大会将于欧洲中部夏令时间10月20日至24日以线上结合线下的形式在西班牙马德里盛启。当前ESMO官网公布的摘要内容显示，来自全球各国家和地区的许多新型免疫治疗方法不断涌现1。【肿瘤资讯】特此整理，以飨读者。
概述
迄今为止，以程序性细胞死亡蛋白-1/配体1（PD-1/L1）单抗为代表的经典免疫检查点抑制剂（ICIs）已为肿瘤学领域熟知，但ESMO摘要中值得关注的ICIs远不止于此：首先是熟悉的面孔，PD-1 x 细胞毒性T淋巴细胞相关抗原-4（CTLA-4）双特异性抗体、PD-1 x CTLA-4双功能组合抗体；其次是聚焦免疫细胞的NK细胞接合器、激活γ9δ2 T细胞的BTN3A单抗；再者还有靶向GUCY2C的CAR-T细胞疗法2（表.免疫治疗相关ESMO摘要一览表）。
研究及产品信息
实体瘤
摘要号及题目：1026MO - A phase 1b/2 study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
产品及机制：Retlirafusp alfa (SHR-1701)；PD-L1/TGF-βRII双特异性抗体
企业：江苏恒瑞（Jiangsu Hengrui Medicine）
摘要号及题目：1019O - Clinical and translational data from the Phase 1 SURPASS trial of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab in solid tumors
产品及机制：ADPA2M4CD8；靶向Mage-A4 TCR-T细胞治疗
企业：Adaptimmune
肉瘤
摘要号及题目：1919MO - Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma
产品及机制：Botensilimab + balstilimab ；CTLA-4单抗+PD-1单抗
企业：Agenus
泌尿
摘要号及题目：1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
产品及机制：Volrustomig；CTLA-4 x PD-1双特异性抗体
企业：阿斯利康（AstraZeneca）
摘要号及题目：1765O - Interim Results From a Phase 1 Study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
产品及机制：Xaluritamig (AMG 509)；Steap1 x CD3 T细胞双特异性抗体（TCE）
企业：安进（Amgen）
宫颈癌
摘要号及题目：743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase II study
产品及机制：QL1706CTLA-4 x PD-1双功能组合抗体
企业：齐鲁（Qilu）
肺癌
摘要号及题目：1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
产品及机制：AZD7789；PD-1 x TIM-3双特异性抗体
企业：阿斯利康（AstraZeneca）
NET及内分泌肿瘤
摘要号及题目：725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
产品及机制：BI 764532；DLL3 x CD3 TCE
企业：勃林格殷格翰（Boehringer-Ingelheim）
血液
摘要号及题目：822O - Activation of γ9δ2 T Cells by ICT01 as a Novel Immunotherapeutic Approach for Relapsed/Refractory Hematologic Cancers (EVICTION Trial)
产品及机制：ICT01；激活γ9δ2 T细胞的BTN3A单抗
企业：Imcheck
摘要号及题目：823O - Preliminary Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the CD123 NK Cell Engager (NKCE) SAR443579 in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)
产品及机制：SAR443579；CD123 NK细胞接合器
企业：赛诺菲（Sanofi）/Innate Pharma
黑色素瘤
摘要号及题目：1017O - NTC-001：A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
产品及机制：BNT221（NEO-PTC-01）；新型抗原靶向T细胞疗法（过继细胞疗法）
企业：BioNTech
结直肠癌
摘要号及题目：1018O - Phase I Study of GCC CAR-T therapy IM96 in Patients With Advanced Colorectal Cancer
产品及机制：IM96；靶向GUCY2C的CAR-T细胞疗法
企业：北京艺妙神州（Beijing Immunochina）
1.ESMO Congress 2023 - Conference Calendar - ESMO Congress 2023. https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/list?
2.ESMO 2023 preview – going beyond PD-1. https://www.oncologypipeline.com/apexonco/sites/default/files/styles/large/public/articles/ESMO2.jpg.
排版编辑：肿瘤资讯-Astrid
苏公网安备32059002004080号
